CCM
Consonance Capital Management Portfolio holdings
AUM
$7.28M
This Quarter Return
+44.06%
1 Year Return
-42.86%
3 Year Return
+319.33%
5 Year Return
+899.35%
10 Year Return
–
AUM
$1.07B
AUM Growth
+$1.07B
(+30%)
Cap. Flow
+$33M
Cap. Flow
% of AUM
3.09%
Top 10 Holdings %
Top 10 Hldgs %
62.56%
Holding
47
New
20
Increased
3
Reduced
9
Closed
9
Top Buys
| 1 |
United Therapeutics
UTHR
|
$80.3M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$79.4M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$72.5M |
| 4 |
Globus Medical
GMED
|
$59.3M |
| 5 |
Keros Therapeutics
KROS
|
$39.3M |
Top Sells
| 1 |
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
|
$113M |
| 2 |
Mersana Therapeutics
MRSN
|
$55M |
| 3 |
APTO
Aptose Biosciences, Inc.
APTO
|
$48M |
| 4 |
Compugen
CGEN
|
$42.9M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
$36.4M |
Sector Composition
| 1 | Healthcare | 92.27% |
| 2 | Financials | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$13.8B
| $80.3M | 7.5% | +528,964 | New | +$80.3M |
|
|
2
Iovance Biotherapeutics
IOVA
$807M
| $79.4M | 7.41% | +1,710,803 | New | +$79.4M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $72.5M | 6.77% | +330,000 | New | +$72.5M |
|
|
TCRR
4
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $71.3M | 6.66% | 584,885 -924,934 | -61% | -$113M |
|
5
Atara Biotherapeutics
ATRA
$84.6M
| $69.3M | 6.48% | 3,532,738 -1,152,789 | -25% | -$22.6M |
|
|
GNMK
6
DELISTED
GenMark Diagnostics, Inc
GNMK
| $65.4M | 6.11% | 4,480,163 -819,700 | -15% | -$12M |
|
|
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
| $64.8M | 6.05% | 893,499 +290,767 | +48% | +$21.1M |
|
|
8
Globus Medical
GMED
$8.27B
| $59.3M | 5.54% | +908,953 | New | +$59.3M |
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $55M | 5.14% | 2,729,709 +360,000 | +15% | +$7.26M |
|
10
MacroGenics
MGNX
$112M
| $52.6M | 4.91% | 2,299,829 -1,447,469 | -39% | -$33.1M |
|
|
11
Keros Therapeutics
KROS
$618M
| $39.3M | 3.67% | +557,095 | New | +$39.3M |
|
|
12
Mersana Therapeutics
MRSN
$36.5M
| $37.3M | 3.48% | 1,401,703 -2,066,468 | -60% | -$55M |
|
13
Arvinas
ARVN
$568M
| $36.1M | 3.37% | +425,000 | New | +$36.1M |
|
|
KDMN
14
DELISTED
Kadmon Holdings, Inc.
KDMN
| $30.5M | 2.85% | 7,349,621 -6,657,927 | -48% | -$27.6M |
|
|
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $27.7M | 2.58% | +484,671 | New | +$27.7M |
|
|
GMDA
16
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $27.6M | 2.58% | +3,287,745 | New | +$27.6M |
|
17
Agios Pharmaceuticals
AGIO
$2.19B
| $27.4M | 2.55% | +631,215 | New | +$27.4M |
|
|
IMGN
18
DELISTED
Immunogen Inc
IMGN
| $22.7M | 2.12% | +3,515,944 | New | +$22.7M |
|
19
CASI Pharmaceuticals
CASI
$35.8M
| $22.4M | 2.09% | 7,576,431 +1,016,431 | +15% | +$3M |
|
20
Verastem
VSTM
$569M
| $16.6M | 1.55% | +7,780,186 | New | +$16.6M |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $16.4M | 1.53% | 2,373,924 -1,471,070 | -38% | -$10.2M |
|
22
Stereotaxis
STXS
$261M
| $16M | 1.49% | 3,135,176 | – | – |
|
23
Assembly Biosciences
ASMB
$190M
| $11.9M | 1.11% | 1,969,875 | – | – |
|
|
CHFW.U
24
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
| $10.5M | 0.98% | +1,000,000 | New | +$10.5M |
|
25
Arcus Biosciences
RCUS
$1.13B
| $10.1M | 0.94% | +387,492 | New | +$10.1M |
|